Work

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes

Year: 2015

Type: article

Abstract: Meeting abstracts Adoptive T cell therapy using tumor-infiltrating lymphocytes (TIL) for patients with metastatic melanoma has been shown to have a 45-50% response rate as demonstrated by multiple institutions worldwide. However, understanding how long infused T cells persist in patients remains

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p22

Authors: Cara Haymaker, Marie-Andrée Forget, Caitlin Creasy, Krit Ritthipichai, Patrick Hwu, Chantale Bernatchez

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490